Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

NEW YORKand SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.

A live webcast of the fireside chat will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral selective estrogen receptor degrader (SERD) for estrogen-receptor-positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego. For more information, please visit www.zentalis.com.

Contacts

Investor Contact:

Thomas Hoffmann

Solebury Trout

1.646.378.2931

[email protected]

Media Contact:

Julia Deutsch

Solebury Trout

1.646.378.2967

[email protected]

You May Also Be Interested In

• XGEN Appoints Two World-Renowned Reproductive Medicine Specialists to Board
• Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
• Chinese AI Models Now Up to 90% Cheaper than US Rivals, Threatening Economics of the US-led AI Boom